Floatz logo

Pembrolizumab

Acute Myeloid Leukemia Post Cytotoxic Therapy

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

78 Active assets in the Acute Myeloid Leukemia Post Cytotoxic Therapy cohort.

Asset / SponsorPhaseRating
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
FILGRASTIM
City of Hope Medical Center
Phase 2/3BBB
Idarubicine
Fred Hutchinson Cancer Center
Phase 2/3BB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →